# 510(k) Summary: 510(k) for the cobas c 501 ISE, Modified Calibration

Introduction

The information in this $5 1 0 ( \mathbf k )$ summary is being submitted in accordance with requirements of 21 CFR 807.92.

Submitter   
name,   
address, and contact

Contact Person: Khoa Tran Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

Phone: (317) -521-3409 Fax: (317) -521-2324 Email: khoa.tran@roche.com

Date Prepared: October 17, 2013

# Device name.

Proprietary name:

cobas c 501 ISE Indirect Na, K, Cl for Gen. 2.

# Common name:

Sodium Test System Potassium Test System Chloride Test System

# Classification:

Ion-Specific Electrode Sodium Ion-Specific Electrode Potassium Ion-Specific Electrode Chloride

Predicate Device

ISE Indirect Na, K, Cl for Gen.2 k053165

# Establishment registration

# Classification

The FDA has classified the Sodium, Potassium, and Chloride Test Systems as Class ⅡI devices.

<table><tr><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Regulation</td></tr><tr><td rowspan=1 colspan=1>ClinicalChemistry (75)</td><td rowspan=1 colspan=1>JGS</td><td rowspan=1 colspan=1>Ion Specific Electrode, Sodium</td><td rowspan=1 colspan=1>21 CFR862.1665</td></tr><tr><td rowspan=1 colspan=1>ClinicalChemistry (75)</td><td rowspan=1 colspan=1>CEM</td><td rowspan=1 colspan=1>Ion Specific Electrode,Potassium</td><td rowspan=1 colspan=1>21 CFR862.1600</td></tr><tr><td rowspan=1 colspan=1>ClinicalChemistry (75)</td><td rowspan=1 colspan=1>CGZ</td><td rowspan=1 colspan=1>Ion Specific Electrode, Chloride</td><td rowspan=1 colspan=1>21 CFR862.1170</td></tr></table>

Draft labeling sufficient to describe the device, its intended use, and the directions for use on the cobas c 501 analyzer module is included in the submission.

The ISE Gen 2 reagent was cleared in k053 165 for application to the Roche/Hitachi family of analyzers.

The cobas 6000 analyzer series with an ISE module is an lon-Selective Electrode (ISE) system for the determination of sodium, potassium, and chloride in serum, plasma, and urine. The cobas 6000 analyzer series, including the cobas c 501 with ISE for Serum, Plasma and Urine sample types was previously cleared in k060373. This premarket notification seeks to obtain FDA review and clearance for the cobas c 501 ISE, Modified Calibration for Serum, Plasma and Urine sample types.

An ISE makes use of the unique properties of certain membrane materials to develop an electrical potential (electromotive force, EMF) for the measurements of ions in solution. The electrode has a selective membrane in contact with both the test solution and an internal filling solution. The internal filling solution contains the test ion at a fixed concentration. Because of the particular nature of the membrane; the test ions will closely associate with the membrane on each side. The membrane EMF is determined by the difference in concentration of the test ion in the test solution and the internal filling solution. The EMF develops according to the Nernst equation for a specific ion in solution (see package insert for further explanation).

Aqueous ISE Standards Low and High were cleared in k053 165. The modified calibration in this submission included the use of ISE Standards Low (S1) and High (S2) for 2-point calibration and the Standard High for compensation (S3). Previously, a serum-based ISE compensator was used for S3 compensation. The modification is switching from serum-based ISE compensator for S3 to ISE Standard High. In the new calibration scheme, the ISE Standard High will be used for both S2 and S3.

# Indications for use

The ISE module of the Roche / Hitachi systems is intended for the quantitative determination of sodium, potassium, and chloride in serum, plasma, or urine using ion-selective electrodes.

Sodium measurements are used in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance.

Potassium measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.

Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.

The following table compares the cobas c 501 ISE Gen. 2, Modified Calibration for Serum, Plasma and Urine sample types toits predicate device, the cobas c 501 analyzer module with ISE Gen.2 reagent, originally cleared in k053165.

Comparison of Systems - similarities and differences

<table><tr><td rowspan=1 colspan=3>System Comparison</td></tr><tr><td rowspan=1 colspan=1>PParametera</td><td rowspan=1 colspan=1>5:Predicate: cobas.c 501 ISEiGen 2 with serum-basedHISECompensatorx*</td><td rowspan=1 colspan=1>9:                                1:-cobas c 501 ISE Gen. 2,i .1.$Modified Calibration,7with ISE Standard High(S3)       o3 s$\a</td></tr><tr><td rowspan=1 colspan=1>Intendeduse</td><td rowspan=1 colspan=1>The ISE module of theRoche/Hitachi cobas csystem is intended for thequantitative determination ofsodium, potassium andchloride in serum, plasma orurine using ion-selectiveelectrodes.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measurementprinciple</td><td rowspan=1 colspan=1>ISE Potentiometry</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagentcontainer</td><td rowspan=1 colspan=1>Plastic bottles closed viascrew caps</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Onboardstorage.temperature</td><td rowspan=1 colspan=1>5-12 °C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ISE Module</td><td rowspan=1 colspan=1>Integrated into cobas c 501analyzer</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>IonSelectiveelectrodes(ISEs)</td><td rowspan=1 colspan=1>Potentiometric chloride,potassium, sodium andreference electrodes</td><td rowspan=1 colspan=1>Same</td></tr></table>

Comparison of   
assays -   
similarities   
and   
differences

(Sodium)

<table><tr><td rowspan=1 colspan=3>Assay ComparisonSodium</td></tr><tr><td rowspan=1 colspan=1>a3Parameteri t :</td><td rowspan=1 colspan=1>aIPredicate: cobas c 501 ISEGen2 with serum-basedi.ISE Compensator</td><td rowspan=1 colspan=1>cobas c 501 ISE Gen. 2Modified Calibration,</td></tr><tr><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L] [mmol/L] [%]Low    124.8     0.36    0.3High   144.9      0.43     0.3PNU   124.9      0.38    0.3PPU    149.2     0.35    0.3</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L] [mmol/L]  [%]Low    84.8       0.2     0.3Med    121.4      0.3     0.3MDL   131.6      0.3     0.2High    176.7      0.3     0.2PNU    126.0      0.2     0.2PPU   148.2      0.3     0.2</td></tr><tr><td rowspan=1 colspan=1>Intermediateprecision(CLSI)</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L] [mmol/L] [%]Low    124.9     0.75    0.6High   144.9     0.77    0.5PNU   124.7     0.75    0.6PPU   149.9     0.80    0.5</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L] [mmol/L] [%]Low    84.8       1.0     1.1Med    121.4      0.8     0.6MDL   131.6      0.7     0.5High   176.7      0.6     0.4PNU   126.0      0.7     0.6PPU   148.2      0.5     0.4</td></tr><tr><td rowspan=1 colspan=1>MethodComparisonto reference(FlamePhotometer</td><td rowspan=1 colspan=1>N=51(Plasma)Days = 3Correlation = 0.993Slope (Bablok) = 0.976Intercept (Bablok) = +2.041Range (X) = 132.7 - 164.1</td><td rowspan=1 colspan=1>N=52 (Plasma)Days = 2Correlation= 0.999Slope (Bablok)= 1.000Intercept (Bablok)= 0.200Range (X) = 86.7 - 172N =51 (Serum)Days = 2Correlation = 0.998Slope (Bablok)= 0.992Intercept (Bablok) = 1.633Range (X) = 97.6 -178</td></tr><tr><td rowspan=1 colspan=1>Methodcomparisonto predicate</td><td rowspan=1 colspan=1>N=51(Plasma)Days = 3Correlation = 0.998Slope (Bablok)= 1.000Intercept (Bablok) = -0.100Range (X) = 131.2 -162.3</td><td rowspan=1 colspan=1>N =52 (PlasmaDays = 2Correlation = 1.000Slope (Bablok)= 1.016Intercept (Bablok)=-1.456Range (X)=87.6-170N=51 (Serum)Days= 2Correlation = 0.999Slope (Bablok)= 1.009Intercept (Bablok)=-0.515Range (X)=97.3-176</td></tr><tr><td rowspan=1 colspan=1>DetectionLimit</td><td rowspan=1 colspan=1>Not determined</td><td rowspan=1 colspan=1>LoB = 3.9 mmol/LLoD = 5.7 mmol/LLoQ= 11.1 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Reportablerange</td><td rowspan=1 colspan=1>80 -180 mmol/L</td><td rowspan=1 colspan=1>80-180 mmol/L</td></tr></table>

Comparison of   
assays  
similarities   
and   
differences   
Comparison of   
assays  
similarities   
and   
differences,   
(Potassium)   
Comparison of   
assays -   
similarities   
and   
differences,   
(Chloride)   
Comparison of   
assays  
similarities   
and   
differences,   
(Chloride)

<table><tr><td colspan="8">Assay Comparison</td></tr><tr><td colspan="8">Sodium - Urine</td></tr><tr><td>Parameter</td><td colspan="4">Predicate: cobas c 501 ISE Gen. 2 with serum-based ISE Compensator 83208 Mean</td><td colspan="3">cobas c501 ISE Gen. 2, Modified Calibration, with ISE Standard High Mean</td></tr><tr><td>Repeatability</td><td>Low High Liq 1 Liq 2</td><td>[mmol/L] 16.7 166.8 76.3 175.5</td><td>SD [mmol/L] 0.27 0.63 0.31 0.47</td><td>CV [%] 1.6 Low 0.4 Med 0.4 MDL 0.3 High Liq 1 Liq 2 CV</td><td>[mmol/L] 30.6 131.7 23.3 236.7 81.6 172.3 Mean</td><td>SD [mmol/L] 0.1 0.2 0.1 0.4 0.2 0.2</td><td>CV [%] 0.2 0.2 0.3 0.2 0.2 0.1 CV</td></tr><tr><td>Intermediate precision (CLSI)</td><td>[mmol/L] Low High Liq 1 Liq 2</td><td>Mean 15.5 166.7 75.7 176.6</td><td>SD [mmol/L] [%] 0.62 4.0 0.87 0.75 1.07 0.6</td><td>Low 0.5 Med 1.0 MDL High Liq 1 Liq 2</td><td>[mmol/L] 30.6 131.7 23.3 236.7 81.6 172.3</td><td>SD [mmol/L] 0.9 0.6 0.9 1.3 1.3 2.6</td><td>[%] 3.0 0.5 3.8 0.6 1.6 1.5</td></tr><tr><td>Method Comparison to reference (flame photometer</td><td colspan="3">N=51 Days = 3 Correlation = 1.000 Slope (Bablok) = 1.001 Intercept (Bablok) = -1.263 Range (X)= 19.9 - 257.4</td><td colspan="3">N = 100 Days = 2 Correlation = 1.000 Slope (Bablok) = 0.964 Intercept (Bablok) = 4.032 Range (X) = 23.5 - 249.8</td><td></td></tr><tr><td>Method comparison to predicate</td><td colspan="3">N=51 Days = 3 Correlation= 1.000 Slope (Bablok) = 1.011 Intercept (Bablok) = -0.247</td><td colspan="3">N =100 Days = 2 Correlation= 1.000 Slope (Bablok) = 0.995 Intercept (Bablok) = 0.687 Range (X) = 25.1 - 245.4</td><td></td></tr><tr><td>Detection Limit</td><td colspan="3">Range (X) = 17.9 -253.0 Not determined</td><td colspan="3">LoB = 3.9 mmol/L LoD = 5.7 mmol/L LoQ = 11.1 mmol/L</td><td></td></tr><tr><td>Reportable range</td><td colspan="3">10-250 mmol/L</td><td colspan="3">20 - 250 mmol/L</td><td></td></tr><tr><td>Extended Range</td><td colspan="3">250-375 mmol/L (samples diluted via rerun function)</td><td colspan="3">250 - 375 mmol/L (samples diluted via rerun function)</td><td></td></tr><tr><td colspan="7">Assay Comparison Potassium</td></tr><tr><td>$\fa$ Parameter * } n $*a}$ - *r ;; *4</td><td colspan="4">3 Predicate: cobas c 501 ISE Gen: 2 with serum-based ISE Compensator 9 $ we a</td><td colspan="2">E e3 cobas c 501 ISE Gen. 2, Modified Calibration, with ISE Standard High</td></tr><tr><td>Repeatability</td><td>Low High PNU PPU</td><td>Mean SD [mmol/L] [mmol/L] 4.68 0.03 8.62 0.04 3.37 0.02 6.06 0.03 </td><td>CV [%] 0.5 0.5 0.5</td><td>Low Med MDL High PNU PPU</td><td>Mean [mmol/L] 1.62 4.97 2.63 9.46 3.57 6.59</td><td>SD [mmol/L] 0.01 0.04 0.02 0.06 0.03 0.04</td><td>CV [%] 0.7 0.7 0.6 0.6 0.8 0.6</td></tr><tr><td>Intermediate precision (CLSI)</td><td>Low High PNU PPU</td><td>Mean SD [mmol/L] [mmol/L] 4.72 0.03 8.63 0.04 3.39 0.02 6.08 0.03</td><td>CV [%] 0.7 0.5 0.5 0.6</td><td>Low Med MDL High PNU PPU</td><td>Mean [mmol/L] 1.62 4.97 2.63 9.46 3.57 6.59</td><td>SD [mmol/L] 0.03 0.04 0.03 0.07 0.04 0.05</td><td>CV [%] 1.6 0.8 1.0 0.7 1.0 0.7</td></tr><tr><td>Method. Comparison to reference (Flame Photometry</td><td colspan="3">N=51(Plasma) Days = 3 Correlation = 0.998 Slope (Bablok)= 0.983 Intercept (Bablok)= -0.026 Range (X) = 3.23 - 6.35</td><td colspan="3">N= 52 (Plasma) Days = 2 Correlation = 1.000 Slope (Bablok)= 1.010 Intercept (Bablok) = - 0.022 Range (X) = 2.1 - 9.19 N=54 (Serum) Days = 2 Correlation= 1.000 Slope (Bablok)= 1.005 Intercept (Bablok)=-0.020 Range (X)= 1.59-9.56 N =52 (Plasma</td></tr><tr><td>comparison to predicate</td><td colspan="3">Days = 3 Correlation = 0.998 Slope (Bablok) = 0.988 Intercept (Bablok) = 0.052 Range (X) = 3.14 -6.26</td><td colspan="2">Days = 2 Correlation= 1.000 Slope (Bablok)=1.008 Intercept (Bablok)=0.018 Range (X) = 2.02 -9.13 N = 54 (Serum) Days = 2 Correlation=1.000 Slope (Bablok) = 1.004 Intercept (Bablok) = 0.302</td><td></td></tr><tr><td>Detection Limit</td><td colspan="3">Not determined</td><td colspan="3">Range (X)= 1.52 - 9.45. LoB = 0.17 mmol/L LoD = 0.24 mmol/L</td></tr><tr><td>Reportable range</td><td colspan="3">1.5-10.0 mmol/L</td><td colspan="3">LoQ= 0.41 mmol/L 1.5 - 10.0 mmol/L</td></tr></table>

Comparison of assays - similarities and differences, (Potassium)

<table><tr><td colspan="6">Assay Comparison</td></tr><tr><td colspan="6">Potassium - Urine Parameter Predicate: cobas c501 ISE cobas c501 ISE Gen. 2</td></tr><tr><td>Repeatability Low</td><td>Gen. 2 with serum-based ISE Compensator Mean [mmol/L] 8.79</td><td>SD CV .[mmol/L] [%] 0.04</td><td>0.4 Low Med</td><td>Modified Calibration, with ISE Standard High Mean [mmol/L] 5.15</td><td>SD CV [mmol/L] [%] 0.03 0.6 0.32 0.6</td></tr><tr><td>Intermediate precision</td><td>High 72.04 Liq 1 31.13 Liq 2 68.76 Mean [mmol/L] Low 8.99</td><td>0.53 0.21 0.36 SD [mmol/L] 0.04</td><td>0.7 0.7 0.5 CV [%] 0.4</td><td>52.08 MDL 15.39 High 90.34 Liq 1 31.48 Liq 2 70.56 Mean [mmol/L] Low 5.15 52.08</td><td>0.09 0.6 0.67 0.7 0.19 0.6 0.43 0.6 SD CV [mmol/L] [%] 0.04</td></tr><tr><td>(CLSI) Method</td><td>High 72.04 Liq 1 31.13 Liq 2 68.76</td><td>0.53 0.21 0.36 N= 51 Days = 3</td><td>0.7 Med 0.7 MDL 0.5 High Liq 1 Liq 2</td><td>0.67 15.39 0.14 90.34 1.38 31.48 0.53 70.56 1.17 N = 105 Days = 2</td><td>0.7 1.3 0.9 1.5 1.7 1.7</td></tr><tr><td>Comparison to reference (Flame Photometry Method</td><td colspan="2">Correlation= 1.000 Slope (Bablok)= 1.033 Intercept (Bablok)= -0.023 Range (X)=9.20-95.10 N=51</td><td colspan="3">Correlation = 1.000 Slope (Bablok) = 1.018 Intercept (Bablok) = 0.397 Range (X)=4.00 -97.20 N = 105</td></tr><tr><td>comparison to predicate</td><td colspan="2">Days = 3 Correlation = 0.999 Slope (Bablok) = 0.982 Intercept (Bablok)= 0.323 Range (X)= 9.68-98.55</td><td colspan="2">Days = 2 Correlation = 0.999 Slope (Bablok) = 0.997 Intercept (Bablok) = 0.062 Range (X) = 4.05 - 97.35</td><td></td></tr><tr><td>Detection Limit</td><td colspan="2">Not determined</td><td colspan="3">LoB = 0.17 mmol/L LoD = 0.24 mmol/L LoQ= 0.41 mmol/L</td></tr><tr><td>Reportable range</td><td colspan="2">1-100 mmol/L</td><td colspan="2">3- 100 mmol/L</td><td></td></tr><tr><td>Extended Range</td><td colspan="2">100-150 mmol/L (samples diluted via rerun function)</td><td colspan="3"></td><td>100 -150 mmol/L (samples diluted via rerun function)</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Assay ComparisonChloride</td></tr><tr><td rowspan=1 colspan=1>&quot;pParameter- T.</td><td rowspan=1 colspan=1>0Predicate: cobas c 501 ISEGen. 2 with serum-based0:ISE Compensator    $\rac{  }$</td><td rowspan=1 colspan=1>;3cobas c 501 ISE Gen. 2Modified Calibration,with ISE Standard High</td></tr><tr><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L] [mmol/L]  [%]Low    86.6      0.30    0.3High   118.4     0.38    0.3PNU    82.1      0.41     0.5PPU   114.7     0.31    0.3</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L][mmol/L] [%]Low    68.5      0.2     0.3Med    129.0      0.4     0.3MDL    92.3       0.2     0.3High   139.0      0.3     0.2PNU    86.2      0.2     0.3PPU   119.2      0.3     0.2</td></tr><tr><td rowspan=1 colspan=1>Intermediateprecision(CLSI)</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L] [mmol/L]  [%]Low    88.2      0.55    0.6High   118.4     0.61    0.5PNU    81.9      0.36    0.4PPU   115.4     0.62    0.5</td><td rowspan=1 colspan=1>Mean      SD     CV[mmol/L] [mmol/L] [%]Low    68.5       0.6     0.8Med    129.0      0.6     0.5MDL    92.3       0.5     0.6High   139.0      0.6     0.4PNU    86.2      0.5     0.6PPU   119.2      0.5     0.4</td></tr><tr><td rowspan=1 colspan=1>MethodComparison toreference(Coulometry)</td><td rowspan=1 colspan=1>N=51 (Plasma)Days = 3Correlation = 0.995Slope (Bablok) = 0.954Intercept (Bablok)=+1.438Range (X) = 92.0 - 132.0</td><td rowspan=1 colspan=1>N =52 (PlasmaDays = 2Correlation= 0.998Slope (Bablok)= 1.023Intercept (Bablok)= -0.769Range (X) = 69.0 - 133N = 53 (Serum)Days = 2Correlation = 0.999Slope (Bablok)= 1.043Intercept (Bablok) = -2.843Range (X) = 62.0 - 136</td></tr><tr><td rowspan=1 colspan=1>Methodcomparison topredicate</td><td rowspan=1 colspan=1>N=51(PlasmaDays = 3Correlation = 0.999Slope (Bablok)= 0.978Intercept (Bablok)=+1.744Range (X) = 90.7 - 128.9</td><td rowspan=1 colspan=1>N = 52 (PlasmaDays = 2Correlation = 0.999Slope (Bablok)= 1.006Intercept (Bablok)= -0.118Range (X)= 69.4 -134N = 53 (Serum)Days= 2Correlation= 1.000Slope (Bablok) = 0.997Intercept (Bablok)= 0.872Range (X) = 61.4 - 138</td></tr><tr><td rowspan=1 colspan=1>DetectionLimit</td><td rowspan=1 colspan=1>Not determined</td><td rowspan=1 colspan=1>LoB = 3.40 mmol/LLoD = 4.7 mmol/LLoQ= 5.5 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Reportablerange</td><td rowspan=1 colspan=1>60 - 140 mmol/L</td><td rowspan=1 colspan=1>60 - 140 mmol/L</td></tr></table>

<table><tr><td colspan="8">Assay Comparison Chloride - Urine</td></tr><tr><td>x 3}$ Parameter 0: . * $\frac}$ ::</td><td colspan="3">919 you4 9e 5r Predicate: cobas c 501 ISE Gen. 2 with serum-based &#x27;4i &quot;y$ 1</td><td colspan="3">al * cobas c 501 ISE Gen 2, $a} A Modified Calibration, with ISE Standard High 4</td></tr><tr><td>Repeatability</td><td>Mean [mimol/L] Low 20.4 High 165.0 Liq 1 101.9 Liq 2 203.0</td><td>SD [mmol/L] 0.29 0.81 0.43 0.54</td><td>CV [%] 1.4 0.5 0.4 0.3</td><td>Low Med MDL High Liq 1 Liq 2</td><td>Mean SD [mmol/L] [mmol/L] 25.8 0.1 131.4 0.3 24.3 0.1 243.4 0.6 97.5 0.2 198.2 0.4 SD</td><td>CV [%] 0.2 0.2 0.3 0.2 0.2 0.2</td></tr><tr><td>Intermediate precision (CLSI)</td><td>Mean [mmol/L] Low 19.9 High 165.4 Liq 1 101.5 Liq 2 206.1</td><td>SD [mmol/L] 0.55 1.17 0.34 1.26</td><td>CV [%] 2.8 0.7 0.3 0.6</td><td>Low Med MDL High Liq 1 Liq 2</td><td>Mean [mmol/L] 25.8 0.6 131.4 0.7 24.3 0.6 243.4 1.8 97.5 1.6 198.2 2.3 $N = =105</td><td>CV [mmol/L] [%] 2.3 0.5 2.4 0.7 1.6 1.2</td></tr><tr><td>Method Comparison to reference (Coulometry)</td><td colspan="3">N = 51 Days = 3 Correlation = 1.000 Slope (Bablok) = 1.002 Intercept (Bablok)= -2.739 Range (X) = 21.0 - 274.0</td><td colspan="3">Days = 2 Correlation = 0.998 Slope (Bablok) = 1.020 Intercept (Bablok)= -1.700 Range (X) = 22.0 - 248.0</td></tr><tr><td>Method comparison to predicate</td><td colspan="3">N=51 Days = 3 Correlation = 1.000 Slope (Bablok) = 1.009 Intercept (Bablok)= -1.715 Range (X)= 18.5 - 269.0</td><td colspan="3">N= 105 Days = 2 Correlation= 1.000 Slope (Bablok) = 0.989 Intercept (Bablok) = 0.669 Range (X) = 21.2 - 249.9</td></tr><tr><td>Detection Limit</td><td colspan="3">Not determined</td><td colspan="3">LoB = 3.4 mmol/L LoD = 4.7 mmol/L LoQ = 5.5 mmol/L</td></tr><tr><td>Reportable range</td><td colspan="3">10 -250 mmol/L</td><td colspan="3">20 - 250 mmol/L</td></tr><tr><td>Extended Range</td><td colspan="3">250 -375 mmol/L (samples diluted via rerun. function)</td><td colspan="3">250 - 375 mmol/L (samples diluted via rerun function)</td></tr></table>

# Conclusion:

The data presented in this premarket notification demonstrates cobas c 501 ISE Gen. 2 assay with the modified calibration performs substantially equivalent to the predicate device, the cobas c 501 ISE Gen. 2 with the original calibration (k053165).

December 18, 2013

# ROCHE DIAGNOSTICS KHOA TRAN REGULATORY AFFAIRS CONSULTANT 9115 HAGUE ROAD INDIANAPOLIS IN 46250

Re: K132418 Trade/Device Name: cobas c 501 ISE Indirect Na, K, Cl for Gen. 2 Regulation Number: 21 CFR 862.1665 Regulation Name: Sodium test system Regulatory Class: II Product Code: JGS, CEM, CGZ Dated: December 12, 2013 Received: December 13, 2013

Dear Mr. Tran:

We have reviewed your Section $5 1 0 ( k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and CosmeticAct (Act) that do not require approval o a premarket approval application (PMA). You may, therefore, market the device, subject t the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.Please note:CRH does not evaluate information related to contract liability warrants.We remind you, however, that device labeling must be truthul and not misleading.

yev  eovin lassSpelcass  A), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2-Mr. Tran

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manuacturers, International andConsumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://wwvy.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.9. For questions regarding the reporting ofadverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/defaulit.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDeviccs/ResourcesforYou/Industrv/default.htm.

Sincerely yours,

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Enclosure

cobas c 501 ISE Indirect Na, K, Cl for Gen. 2 Indications for Use (Describe)

The ISEmoulheRoHitastes ntende r e quantitativedeteriationdi, poass and chloride in serum, plasma, or urine using ion-selective electrodes.

Sodium measurements are used in the diagnosis and treatment of aldosteronism (excessive secretion of the homone aldosterone, dabetesinsipidushroniexcretionaremountsdiluteuri ccpan y exhrsrealypensiis'issausby tinherel an y inappropriateantidiuretichormone secretion, orother diseases involving electrolyte imbalance. Potassium measurements are used to monitor electrolyte balance in the diagnosis and treatment of disease conditions characterized by low or high blood potassium levels.Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.

Yung W. Chan -S